Moleac launches CognivAiD™, a novel targeted product for vascular dementia
CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.
- CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.
- SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Moleac announced on 29th October 2022 the launch of CognivAiD™, the first-in-market specific product for Vascular Dementia (VaD).
- David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives.
- Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases 2 .